AIMS/HYPOTHESIS: Functional and common Arg16Gly and Gln27Glu polymorphisms have been identified in ADRB2, the gene encoding the beta2-adrenergic receptor. These variants have previously been examined for association with obesity, hypertension and diabetes with inconclusive results. MATERIALS AND METHODS: We investigated both of these variants in 7,808 unrelated, middle-aged white people for their association with obesity in a case-control study, quantitative trait analysis and meta-analysis. Moreover, both variants were investigated for their potential influence on measures of hypertension and type 2 diabetes by case-control and quantitative trait analyses. RESULTS: The present study did not find consistent evidence for an association of these beta2-adrenergic receptor variants with obesity or hypertension; neither did the quantitative trait analyses show any effect of the variants on obesity-related traits. However, both the Gly allele of the Arg16Gly variant and the Glu allele of the Gln27Glu variant showed nominal association with systolic blood pressure. Furthermore, there was a nominal association of the Arg16 allele frequency and genotype distribution with type 2 diabetes; however, no influence on quantitative biochemical phenotypes related to type 2 diabetes was found. A nominal association of the Arg/Gly genotype with the metabolic syndrome was also observed (p=0.003). Logistic regression analyses provided no evidence of a synergistic or an additive effect of these variants on obesity, hypertension or diabetes. CONCLUSIONS/ INTERPRETATION: After studying 7,808 middle-aged white subjects, we were unable to demonstrate any consistent associations between two common amino acid polymorphisms of the beta2-adrenergic receptor and obesity, hypertension or type 2 diabetes.
AIMS/HYPOTHESIS: Functional and common Arg16Gly and Gln27Glu polymorphisms have been identified in ADRB2, the gene encoding the beta2-adrenergic receptor. These variants have previously been examined for association with obesity, hypertension and diabetes with inconclusive results. MATERIALS AND METHODS: We investigated both of these variants in 7,808 unrelated, middle-aged white people for their association with obesity in a case-control study, quantitative trait analysis and meta-analysis. Moreover, both variants were investigated for their potential influence on measures of hypertension and type 2 diabetes by case-control and quantitative trait analyses. RESULTS: The present study did not find consistent evidence for an association of these beta2-adrenergic receptor variants with obesity or hypertension; neither did the quantitative trait analyses show any effect of the variants on obesity-related traits. However, both the Gly allele of the Arg16Gly variant and the Glu allele of the Gln27Glu variant showed nominal association with systolic blood pressure. Furthermore, there was a nominal association of the Arg16 allele frequency and genotype distribution with type 2 diabetes; however, no influence on quantitative biochemical phenotypes related to type 2 diabetes was found. A nominal association of the Arg/Gly genotype with the metabolic syndrome was also observed (p=0.003). Logistic regression analyses provided no evidence of a synergistic or an additive effect of these variants on obesity, hypertension or diabetes. CONCLUSIONS/ INTERPRETATION: After studying 7,808 middle-aged white subjects, we were unable to demonstrate any consistent associations between two common amino acid polymorphisms of the beta2-adrenergic receptor and obesity, hypertension or type 2 diabetes.
Authors: Y Mori; H Kim-Motoyama; Y Ito; T Katakura; K Yasuda; S Ishiyama-Shigemoto; K Yamada; Y Akanuma; Y Ohashi; S Kimura; Y Yazaki; T Kadowaki Journal: Biochem Biophys Res Commun Date: 1999-04-29 Impact factor: 3.575
Authors: N Iwamoto; Y Ogawa; S Kajihara; A Hisatomi; T Yasutake; T Yoshimura; T Mizuta; T Hara; I Ozaki; K Yamamoto Journal: Clin Chim Acta Date: 2001-12 Impact factor: 3.786
Authors: A Busjahn; G H Li; H D Faulhaber; M Rosenthal; A Becker; E Jeschke; H Schuster; B Timmermann; M R Hoehe; F C Luft Journal: Hypertension Date: 2000-02 Impact factor: 10.190
Authors: V Large; L Hellström; S Reynisdottir; F Lönnqvist; P Eriksson; L Lannfelt; P Arner Journal: J Clin Invest Date: 1997-12-15 Impact factor: 14.808
Authors: J L González Sánchez; A M Proenza; M T Martínez Larrad; J M Ramis; C Fernández Pérez; A Palou; M Serrano Ríos Journal: Clin Endocrinol (Oxf) Date: 2003-10 Impact factor: 3.478
Authors: D L Ellsworth; S A Coady; Wei Chen; S R Srinivasan; A Elkasabany; J Gustat; E Boerwinkle; G S Berenson Journal: Int J Obes Relat Metab Disord Date: 2002-07
Authors: K H Buetow; M Edmonson; R MacDonald; R Clifford; P Yip; J Kelley; D P Little; R Strausberg; H Koester; C R Cantor; A Braun Journal: Proc Natl Acad Sci U S A Date: 2001-01-02 Impact factor: 11.205
Authors: Magda M Atala; Alessandra Goulart; Grazia M Guerra; Cristiano Mostarda; Bruno Rodrigues; Priscila R Mello; Dulce E Casarine; Maria-Claudia Irigoyen; Alexandre C Pereira; Fernanda M Consolim-Colombo Journal: Am J Transl Res Date: 2015-01-15 Impact factor: 4.060
Authors: Uthra Rajamani; Andrew R Gross; Brooke E Hjelm; Adolfo Sequeira; Marquis P Vawter; Jie Tang; Vineela Gangalapudi; Yizhou Wang; Allen M Andres; Roberta A Gottlieb; Dhruv Sareen Journal: Cell Stem Cell Date: 2018-04-19 Impact factor: 24.633
Authors: Augusto A Litonjua; Li Gong; Qing Ling Duan; Jaekyu Shin; Mariellen J Moore; Scott T Weiss; Julie A Johnson; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2010-01 Impact factor: 2.089
Authors: Avonne Connor; Richard N Baumgartner; Richard A Kerber; Elizabeth O'Brien; Shesh N Rai; Roger K Wolff; Martha L Slattery; Anna R Giuliano; Betsy C Risendal; Tim E Byers; Kathy B Baumgartner Journal: Cancer Causes Control Date: 2012-08-05 Impact factor: 2.506
Authors: Hannah C Cox; Claire Bellis; Rod A Lea; Sharon Quinlan; Roger Hughes; Thomas Dyer; Jac Charlesworth; John Blangero; Lyn R Griffiths Journal: Hum Hered Date: 2009-04-01 Impact factor: 0.444